Trade Quince Therapeuticks Inc - QNCX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0636 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.6882 |
| Open | 1.6482 |
| 1-Year Change | 22.37% |
| Day's Range | 1.6282 - 1.6982 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 17, 2025 | 1.6282 | -0.0500 | -2.98% | 1.6782 | 1.6982 | 1.6282 |
| Jan 16, 2025 | 1.6882 | -0.0100 | -0.59% | 1.6982 | 1.7182 | 1.6882 |
| Jan 15, 2025 | 1.6982 | 0.0000 | 0.00% | 1.6982 | 1.7582 | 1.6782 |
| Jan 14, 2025 | 1.6782 | -0.0100 | -0.59% | 1.6882 | 1.6982 | 1.6682 |
| Jan 13, 2025 | 1.7082 | -0.0600 | -3.39% | 1.7682 | 1.7882 | 1.6782 |
| Jan 10, 2025 | 1.7482 | -0.1100 | -5.92% | 1.8582 | 1.8782 | 1.7282 |
| Jan 8, 2025 | 1.8482 | 0.0100 | 0.54% | 1.8382 | 1.8582 | 1.8182 |
| Jan 7, 2025 | 1.8782 | -0.0300 | -1.57% | 1.9082 | 1.9082 | 1.8482 |
| Jan 6, 2025 | 1.9482 | 0.0100 | 0.52% | 1.9382 | 1.9782 | 1.9082 |
| Jan 3, 2025 | 1.8782 | 0.0200 | 1.08% | 1.8582 | 1.9182 | 1.8382 |
| Jan 2, 2025 | 1.8282 | -0.0200 | -1.08% | 1.8482 | 1.8882 | 1.8282 |
| Dec 31, 2024 | 1.8082 | 0.0400 | 2.26% | 1.7682 | 1.8282 | 1.7482 |
| Dec 30, 2024 | 1.7882 | -0.0300 | -1.65% | 1.8182 | 1.8982 | 1.7682 |
| Dec 27, 2024 | 1.8782 | 0.1400 | 8.05% | 1.7382 | 1.9182 | 1.7382 |
| Dec 26, 2024 | 1.7382 | 0.0300 | 1.76% | 1.7082 | 1.7482 | 1.6382 |
| Dec 24, 2024 | 1.6782 | 0.0200 | 1.21% | 1.6582 | 1.7182 | 1.6582 |
| Dec 23, 2024 | 1.7082 | -0.0500 | -2.84% | 1.7582 | 1.7782 | 1.6682 |
| Dec 20, 2024 | 1.7682 | 0.0500 | 2.91% | 1.7182 | 1.7682 | 1.7182 |
| Dec 19, 2024 | 1.7282 | -0.0800 | -4.42% | 1.8082 | 1.8082 | 1.7182 |
| Dec 18, 2024 | 1.8382 | -0.0800 | -4.17% | 1.9182 | 1.9282 | 1.8182 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cortexyme Inc. Company profile
About Cortexyme Inc
Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
601 Gateway Boulevard, Suite 1250
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com